LH
Laboratory Corp of America Holdings
Laboratory Corp of America Holdings historical holders
total: 10
Ariel Appreciation Fund Laboratory Corp of America Holdings transactions over time
- Total transactions:
- 19
- New positions:
- 1
- Added:
- 5
- Reduced:
- 13
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
John W. Rogers Jr. has been an institutional investor in Laboratory Corp of America Holdings (LH) since 2019 Q3. According to 2026 Q1 report, John W. Rogers Jr. holds 93,200 shares with a market value of roughly $24.87M representing 2.84% of their equity portfolio. The fund/company first acquired LH in 2019 Q3, initially purchasing 313,700 shares. Since the initial investment, Ariel Appreciation Fund has made 18 more transactions in this position.
Does John W. Rogers Jr. still hold LH?
Yes, John W. Rogers Jr. continues to hold Laboratory Corp of America Holdings (LH). According to their 2026 Q1 report, they maintain a position of 93,200 shares valued at approximately $24.87M, representing 2.84% of their equity portfolio.
When did John W. Rogers Jr. first invest in LH?
John W. Rogers Jr. first invested in Laboratory Corp of America Holdings (LH) in 2019 Q3 at the reported quarter-end price of $168.00 per share, acquiring 313,700 shares in their initial purchase.
What is John W. Rogers Jr.'s average cost basis for LH?
Based on historical transaction data, John W. Rogers Jr.'s estimated cost basis for Laboratory Corp of America Holdings (LH) is approximately $180.72 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $180.72
- Weighted AVG sell price:
- $201.01
LH transactions history by Ariel Appreciation Fund
19 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
2.84%
|
93,200
|
$266.81
|
$24,866,692
|
-6.82% (-6,826)
|
-0.2%
|
|
2025 Q1
|
2.74%
|
100,026
|
$232.74
|
$23,280,051
|
-14.70% (-17,235)
|
-0.42%
|
|
2024 Q4
|
2.81%
|
117,261
|
$229.32
|
$26,890,293
|
-6.41% (-8,033)
|
-0.18%
|
|
2024 Q3
|
2.77%
|
125,294
|
$223.48
|
$28,000,703
|
-15.18% (-22,431)
|
-0.52%
|
|
2024 Q2
|
3.12%
|
147,725
|
$203.51
|
$30,063,515
|
-3.26% (-4,982)
|
-0.09%
|
|
2023 Q4
|
3.25%
|
152,707
|
$227.29
|
$34,708,774
|
-10.75% (-18,391)
|
-0.41%
|
|
2023 Q2
|
3.72%
|
171,098
|
$241.33
|
$41,291,080
|
-5.00% (-9,008)
|
-0.19%
|
|
2023 Q1
|
3.60%
|
180,106
|
$229.42
|
$41,319,919
|
+2.87% (+5,027)
|
+0.1%
|
|
2022 Q4
|
3.62%
|
175,079
|
$235.48
|
$41,227,603
|
+5.09% (+8,483)
|
+0.18%
|
|
2022 Q2
|
3.56%
|
166,596
|
$234.36
|
$39,043,439
|
+6.62% (+10,339)
|
+0.22%
|
|
2021 Q4
|
3.51%
|
$314.21
|
+13.90% (+19,067)
|
|||
|
2021 Q3
|
2.83%
|
$281.44
|
-21.61% (-37,810)
|
|||
|
2021 Q2
|
3.42%
|
$275.85
|
-5.76% (-10,700)
|
|||
|
2020 Q4
|
3.22%
|
$203.55
|
+4.44% (+7,900)
|
|||
|
2020 Q3
|
3.47%
|
$188.27
|
-10.16% (-20,100)
|
|||
|
2020 Q2
|
3.44%
|
$166.11
|
-20.71% (-51,700)
|
|||
|
2020 Q1
|
3.71%
|
$126.39
|
-17.89% (-54,400)
|
|||
|
2019 Q4
|
3.91%
|
$169.17
|
-3.09% (-9,700)
|
|||
|
2019 Q3
|
4.07%
|
$168.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.